Literature DB >> 15741969

Drug safety on trial. Last year's withdrawal of the anti-arthritis drug Vioxx triggered a debate about how to better monitor drug safety even after approval.

Mark Greener.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15741969      PMCID： PMC1299263          DOI： 10.1038/sj.embor.7400353

Source DB:  PubMed          Journal:  EMBO Rep        ISSN： 1469-221X            Impact factor:   8.807


× No keyword cloud information.
  5 in total

1.  Attitudinal survey of voluntary reporting of adverse drug reactions.

Authors:  I A Eland; K J Belton; A C van Grootheest; A P Meiners; M D Rawlins; B H Stricker
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

2.  The price of innovation: new estimates of drug development costs.

Authors:  Joseph A DiMasi; Ronald W Hansen; Henry G Grabowski
Journal:  J Health Econ       Date:  2003-03       Impact factor: 3.883

Review 3.  Cutting the cost of drug development?

Authors:  Michael D Rawlins
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

4.  Failing the public health--rofecoxib, Merck, and the FDA.

Authors:  Eric J Topol
Journal:  N Engl J Med       Date:  2004-10-06       Impact factor: 91.245

5.  How to avoid another 'Vioxx'.

Authors:  Simon Frantz
Journal:  Nat Rev Drug Discov       Date:  2005-01       Impact factor: 84.694
  5 in total
  5 in total

1.  The value of observational cohort studies for cancer drugs.

Authors:  David R Spigel
Journal:  Biotechnol Healthc       Date:  2010

2.  First do no harm. Improving drug safety through legislation and independent research.

Authors:  Mark Greener
Journal:  EMBO Rep       Date:  2008-03       Impact factor: 8.807

3.  Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis.

Authors:  Igho J Onakpoya; Carl J Heneghan; Jeffrey K Aronson
Journal:  BMC Med       Date:  2015-02-05       Impact factor: 8.775

4.  Synthesis and diverse biological activity profile of triethylammonium isatin-3-hydrazones.

Authors:  Andrei Bogdanov; Olga Tsivileva; Alexandra Voloshina; Anna Lyubina; Syumbelya Amerhanova; Ekaterina Burtceva; Sergey Bukharov; Alexander Samorodov; Valentin Pavlov
Journal:  ADMET DMPK       Date:  2022-01-12

5.  Elucidating the anticancer activities of guanidinium-functionalized amphiphilic random copolymers by varying the structure and composition in the hydrophobic monomer.

Authors:  Joyce Tay; Yanli Zhao; James L Hedrick; Yi Yan Yang
Journal:  Theranostics       Date:  2021-08-21       Impact factor: 11.556
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.